BR9407958A - Composiçao para uso anti-inflamatório oftálmico ou otolaringológico - Google Patents

Composiçao para uso anti-inflamatório oftálmico ou otolaringológico

Info

Publication number
BR9407958A
BR9407958A BR9407958A BR9407958A BR9407958A BR 9407958 A BR9407958 A BR 9407958A BR 9407958 A BR9407958 A BR 9407958A BR 9407958 A BR9407958 A BR 9407958A BR 9407958 A BR9407958 A BR 9407958A
Authority
BR
Brazil
Prior art keywords
ophthalmic
composition
inflammatory use
otolaryngological
steroid drugs
Prior art date
Application number
BR9407958A
Other languages
English (en)
Inventor
Yaacov J Guy
Doron Friedman
Original Assignee
Pharmos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmos Corp filed Critical Pharmos Corp
Publication of BR9407958A publication Critical patent/BR9407958A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Resins (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Electroluminescent Light Sources (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Adhesives Or Adhesive Processes (AREA)
BR9407958A 1993-10-25 1994-10-21 Composiçao para uso anti-inflamatório oftálmico ou otolaringológico BR9407958A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/142,743 US5540930A (en) 1993-10-25 1993-10-25 Suspension of loteprednol etabonate for ear, eye, or nose treatment
PCT/US1994/012059 WO1995011669A1 (en) 1993-10-25 1994-10-21 Suspension of loteprednol etabonate

Publications (1)

Publication Number Publication Date
BR9407958A true BR9407958A (pt) 1996-11-26

Family

ID=22501105

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9407958A BR9407958A (pt) 1993-10-25 1994-10-21 Composiçao para uso anti-inflamatório oftálmico ou otolaringológico

Country Status (17)

Country Link
US (2) US5540930A (pt)
EP (1) EP0730443B1 (pt)
JP (1) JP3570720B2 (pt)
KR (1) KR100341497B1 (pt)
AT (1) ATE217523T1 (pt)
AU (1) AU697617B2 (pt)
BR (1) BR9407958A (pt)
CA (1) CA2174550C (pt)
DE (1) DE69430635T2 (pt)
DK (1) DK0730443T3 (pt)
ES (1) ES2179851T3 (pt)
HU (1) HU227316B1 (pt)
IL (1) IL111402A (pt)
NZ (1) NZ275749A (pt)
PT (1) PT730443E (pt)
SG (1) SG48768A1 (pt)
WO (1) WO1995011669A1 (pt)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849263A (en) * 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
US5576311A (en) * 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
US5955097A (en) 1996-10-18 1999-09-21 Virotex Corporation Pharmaceutical preparation applicable to mucosal surfaces and body tissues
US5800832A (en) * 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
TW503113B (en) 1997-01-16 2002-09-21 Senju Pharma Co Aqueous suspension for nasal administration
KR100508227B1 (ko) * 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
US20050048102A1 (en) * 1997-10-16 2005-03-03 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
CA2318642A1 (en) * 1998-01-22 1999-07-29 Santen Pharmaceutical Co., Ltd. Fluorometholone ophthalmic suspension
US6103266A (en) * 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
AU757896B2 (en) * 1998-09-02 2003-03-13 Allergan, Inc. Preserved cyclodextrin-containing compositions
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
TR200103694T2 (tr) * 1999-06-22 2002-04-22 Boehringer Ingelheim International Gmbh Sabit ksilometazolin ve oksimetazolin çözeltisi
FR2796553B1 (fr) * 1999-07-22 2001-09-28 Warner Lambert Co Suspension de tixocortol pivalate, collutoire a base de celle-ci et conditionnement la contenant
TR200200737T2 (tr) 1999-09-24 2002-08-21 Alcon, Inc. Siproflaksasin ve deksametazon içeren lokal süspansiyon formülasyonları
CA2356177A1 (en) * 1999-10-20 2001-04-26 Kazuya Takanashi Aqueous pharmaceutical compositions
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
US20040097486A1 (en) * 1999-11-18 2004-05-20 Yanni John M. Use of an H1 antagonist and a safe steroid to treat eye conditions
AU772406B2 (en) * 1999-11-18 2004-04-29 Alcon Inc. Use of H1 antagonist and a safe steroid to treat eye conditions
US20030165568A1 (en) * 2000-05-15 2003-09-04 Giuseppe Colombo Stabilized steroidal suspension
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
CA2412575C (en) 2000-07-26 2009-12-29 Onkar N. Singh Improved process for manufacturing compositions containing ciprofloxacin and hydrocortisone
US20040077562A1 (en) * 2000-11-15 2004-04-22 Chandavarkar Mohan A. Combination drug
AU1770901A (en) * 2000-11-16 2002-05-27 Alcon Lab Inc Combination therapy for lowering and controlling intraocular pressure
AU2002333671B2 (en) 2001-09-21 2006-07-20 Novartis Ag Method of treating middle ear infections
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
US20090215735A1 (en) * 2002-02-25 2009-08-27 Alcon, Inc. Topical solution formulations containing a corticosteroid and a cyclodextrin
WO2004006957A1 (en) * 2002-07-15 2004-01-22 Alcon, Inc. Pharmaceutical compositions for otic use
US7758883B2 (en) * 2002-10-18 2010-07-20 Aqueous Pharma Limited Three layer artificial tear formulation
AU2003301129A1 (en) * 2002-12-20 2004-07-22 Control Delivery Systems, Inc. Steroid compositions for intraocular use
JP4500261B2 (ja) 2003-01-21 2010-07-14 千寿製薬株式会社 ２−アミノ−３−（４−ブロモベンゾイル）フェニル酢酸含有水性液剤
US20050069590A1 (en) * 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
US20050197303A1 (en) * 2003-10-31 2005-09-08 Bausch & Lomb Incorporated Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
JP2007510723A (ja) * 2003-11-03 2007-04-26 ノートン　ヘルスケアー　リミテッド ドライパウダー吸入器で使用するためのソフトステロイド組成物
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
WO2005053708A1 (ja) * 2003-12-02 2005-06-16 Senju Pharmaceutical Co., Ltd. ロテプレドノールエタボネート水性懸濁液剤
PE20050941A1 (es) 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
JP2007518804A (ja) * 2004-01-20 2007-07-12 アラーガン、インコーポレイテッド トリアムシノロンアセトニドおよびヒアルロン酸を好ましく含有する眼局所治療用組成物
US8957034B2 (en) * 2004-01-28 2015-02-17 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
US20050182039A1 (en) * 2004-02-13 2005-08-18 Bausch & Lomb Incorporated Use of Loteprednol etabonate for the treatment of dry eye
ES2330762T3 (es) * 2004-03-25 2009-12-15 BAUSCH & LOMB INCORPORATED Uso de etabonato de loteprednol para el tratamiento del ojo seco.
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
JP2008505978A (ja) * 2004-07-12 2008-02-28 アラーガン、インコーポレイテッド 眼病用組成物および眼病治療法
CA2580659C (en) * 2004-09-15 2013-02-26 Ivx Animal Health, Inc. Corticosteroid having low systemic absorption
US20060257487A1 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
EP1906916B1 (en) * 2005-05-10 2008-10-29 Alcon Inc. Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
EA200800950A1 (ru) * 2005-09-26 2008-08-29 ПЬЕДМОН ФАРМАСЬЮТИКАЛЗ ЭлЭлСи Способы лечения и профилактики среднего отита с применением неионных поверхностно-активных веществ для облегчения трансмембранного введения лекарственного средства в среднее ухо
AU2006295236A1 (en) * 2005-09-26 2007-04-05 Piedmont Pharmaceuticals Llc Methods for treatment and prevention of otitis media using chemical penetration enhancers to facilitate transmembrane drug delivery into the middle ear
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
CN101394834A (zh) 2005-10-18 2009-03-25 阿勒根公司 用糖皮质激素衍生物选择性渗透后段组织来治疗眼睛
US20070093461A1 (en) * 2005-10-26 2007-04-26 Bausch & Lomb Incorporated Effect of Loteprednol etabonate on vascular dysfunction
US20070110812A1 (en) * 2005-11-14 2007-05-17 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
US20070128251A1 (en) * 2005-12-07 2007-06-07 Piedmont Pharmaceuticals, Inc. Process for manufacturing chewable dosage forms for drug delivery and products thereof
US7955632B2 (en) * 2005-12-07 2011-06-07 Bayer B.V. Process for manufacturing chewable dosage forms for drug delivery and products thereof
KR20090010953A (ko) * 2006-03-28 2009-01-30 자블린 파머슈티칼스 인코포레이티드 저 복용량의 비-스테로이드성 항염증성 약물 및 베타-사이클로덱스트린 제형
KR20160033796A (ko) 2006-03-28 2016-03-28 자블린 파머슈티칼스 인코포레이티드 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
US20070238789A1 (en) * 2006-03-31 2007-10-11 Chin-Ming Chang Prednisolone acetate compositions
WO2008002118A1 (es) * 2006-06-27 2008-01-03 Arturo Jimenez Bayardo Una formulación oftálmica en suspensión de etabonato de loteprednol y clorhidrato de ciprofloxacina
AU2007275581B2 (en) 2006-07-21 2011-09-08 Biodelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
WO2008027340A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
WO2008027341A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
DE602007012559D1 (de) * 2006-09-08 2011-03-31 Univ Johns Hopkins H die schleimhaut
TWI415629B (zh) * 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
EP2089035A1 (en) * 2006-11-02 2009-08-19 Riolan Technologies, Inc. Method for treating blepharitis
US20080119448A1 (en) * 2006-11-02 2008-05-22 Friedlaender Mitchell H Methods of treating an ocular allergy with low dose dexamethasone
CN101721714B (zh) * 2009-12-18 2011-12-07 重庆莱美药业股份有限公司 实体瘤被动靶向性抗癌前药及其制备方法
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins PROLONGED DELIVERY OF THERAPEUTIC AGENTS TO AN OCULAR COMPARTMENT
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
CA2833596A1 (en) * 2011-04-22 2012-10-26 Alcon Research, Ltd. Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents
BR112014003651B1 (pt) 2011-08-18 2022-03-29 Biodelivery Sciences International, Inc Dispositivos mucoadesivos resistentes ao mau uso para a liberação de buprenorfina
AU2012312816A1 (en) 2011-09-22 2014-04-24 Bausch & Lomb Incorporated Ophthalmic gel compositions
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
CA2867381C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
CN104394891B (zh) 2012-03-16 2019-04-16 约翰霍普金斯大学 用于递送活性剂的非线性多嵌段共聚物-药物结合物
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
JP6360039B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
NZ742005A (en) * 2012-05-03 2019-04-26 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
CA2871745C (en) 2012-05-03 2023-01-24 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) * 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
CA2872519C (en) 2012-05-04 2017-09-05 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
CN103565742A (zh) * 2012-07-25 2014-02-12 天津金耀集团有限公司 氟米龙滴眼液
CN103565740A (zh) * 2012-07-25 2014-02-12 天津金耀集团有限公司 依碳氯替泼诺混悬滴眼液
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX355330B (es) 2013-11-01 2018-04-16 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapeuticos y sus usos.
DK3216451T3 (da) * 2014-11-07 2022-05-23 Santen Pharmaceutical Co Ltd Oftalmisk vandig sammensætning
US10485757B2 (en) 2015-01-27 2019-11-26 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
CN106279324A (zh) * 2015-05-27 2017-01-04 天津金耀集团有限公司 依碳氯替泼诺一水合物及其晶型与制备方法
CN106279325A (zh) * 2015-05-27 2017-01-04 天津金耀集团有限公司 一种依碳氯替泼诺新晶型及其制备方法
CN106892953A (zh) * 2015-12-21 2017-06-27 天津金耀集团有限公司 依碳氯替泼诺一水合物及其晶型与制备方法
CN106892952A (zh) * 2015-12-21 2017-06-27 天津金耀集团有限公司 一种依碳氯替泼诺新晶型及其制备方法
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20190051010A (ko) 2016-09-08 2019-05-14 칼라 파마슈티컬스, 인크. 치료 화합물의 결정형 및 그의 용도
US12023344B2 (en) 2022-05-25 2024-07-02 Famygen Life Sciences, Inc. Topical otic, ophthalmic, and nasal corticosteroid formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4710495A (en) * 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
JPS6041607A (ja) * 1983-08-12 1985-03-05 Otsuka Pharmaceut Co Ltd 軟膏基剤
JPS6143114A (ja) * 1984-08-03 1986-03-01 Takeda Chem Ind Ltd 虹彩・毛様体疾患治療用眼局所投与剤
US5192535A (en) * 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US5149693A (en) * 1988-03-09 1992-09-22 Alcon Laboratories, Inc. Combination of tobramycin and fluorometholone for topical ophthalmic use
NL8801670A (nl) * 1988-07-01 1990-02-01 Walter Adrianus Josephus Johan Farmaceutisch preparaat.
CA2003198C (en) * 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5277901A (en) * 1990-01-05 1994-01-11 Allergan, Inc. Ophthalmic compositions and methods for preserving and using same

Also Published As

Publication number Publication date
KR960705541A (ko) 1996-11-08
SG48768A1 (en) 1998-05-18
HUT74882A (en) 1997-02-28
KR100341497B1 (ko) 2002-12-05
AU697617B2 (en) 1998-10-15
DE69430635D1 (de) 2002-06-20
EP0730443A4 (en) 1997-11-05
IL111402A (en) 2000-12-06
DE69430635T2 (de) 2003-01-02
HU9601081D0 (en) 1996-06-28
ATE217523T1 (de) 2002-06-15
WO1995011669A1 (en) 1995-05-04
JP3570720B2 (ja) 2004-09-29
EP0730443A1 (en) 1996-09-11
NZ275749A (en) 1998-02-26
ES2179851T3 (es) 2003-02-01
HU227316B1 (en) 2011-03-28
IL111402A0 (en) 1994-12-29
DK0730443T3 (da) 2002-09-09
AU7983594A (en) 1995-05-22
CA2174550A1 (en) 1995-05-04
JPH09504294A (ja) 1997-04-28
PT730443E (pt) 2002-11-29
US5540930A (en) 1996-07-30
EP0730443B1 (en) 2002-05-15
US5747061A (en) 1998-05-05
CA2174550C (en) 2002-10-01

Similar Documents

Publication Publication Date Title
BR9407958A (pt) Composiçao para uso anti-inflamatório oftálmico ou otolaringológico
ES2139360T3 (es) Preparaciones de suspensiones de peptidos o proteinas.
DE59409568D1 (de) Wirkstoffe und gas enthaltende mikropartikel
CA2293382A1 (en) Piperazine derivatives and their use as anti-inflammatory agents
ATE395042T1 (de) Darreichungsformen welche mikropartikel und treibgas enthalten
MX9700223A (es) Composicion farmaceutica para la liberacion controlada de moguisteina en una suspension liquida.
BR9507917A (pt) Reagente para preparar um agente radiofarmacêutico agente formador de imagem processo para preparar o mesmo kit para preparar uma preparação farmacêutica uso do reagente agente radioterapêutico composição e agente radiofarmacêutico
EP0875244A3 (en) Cosmetically accceptable microstructured compositions
ES2088975T3 (es) Sistemas vehiculo para uso en composiciones cosmeticas.
CA2139381A1 (en) Guar as drift control agent
CA2292673A1 (en) Pharmaceutical compositions containing eletriptan hemisulphate
UA27899C2 (uk) Порошкова антибактеріальна композиція, що призначена для орального використання, яка містить гідратований цефтибутен
CA2171446A1 (en) Pseudo- and non-peptide bradykinin receptor antagonists
ATE286941T1 (de) Wässrige bindemitteldispersionen, überzugsmittel und deren verwendung
AU5185299A (en) Granular compositions
CA2176223A1 (en) Fenbendazole formulations
GR1001511B (el) Στεροειδείς συν?έσεις.
IT1277663B1 (it) Sospensioni acquose stabili di mesalazina per uso topico
GB0128210D0 (en) Compositions containing saccharide and hydrophobic silica
BR0009557A (pt) Suspensão farmacêutica para beber de ibuprofeno
BR9713060A (pt) Análogos de lh-rh estruturalmente submetidos, os seus usos e as composições farmacêuticas contendo-os.
AR002256A1 (es) Composicion anti-inflamatoria, util para uso oftamologico y otorilaringologico
AU3987997A (en) Use of novel organoselenium compounds as pro-oxidizing agents, their methods of preparation and pharmaceutical compositions and application thereof
ITMI932767A1 (it) Derivati policiclici di oxo-azasteroidi inibitori dell'enzima 5-alfa riduttasi, loro uso come antiandrogeni e composizioni farmaceutiche che li contengono
WO1991019475A1 (en) Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene d¿4?

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal
CKFC Appeal: appeal against refusal
B25G Requested change of headquarter approved
B25A Requested transfer of rights approved

Owner name: BAUSCH AND LOMB INCOPORATED (US)

Free format text: TRANSFERIDO DE: PHARMOS CORPORATION

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]